Cancer

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

NMPA approves first bispecific antibody-drug conjugate: a new treatment for nasopharyngeal carcinoma

Analytical Development Project for WPD401

Mabion Completes Analytical Development Project for WPD401

Official announcement by the Ministry of Health regarding the ruling on the contract for COVID-19 vaccines produced by Pfizer.

The PLN 5.6 Billion Bill for COVID-19 Vaccines

Declaration of the objectives and scope of the European Biotech Act

Declaration of the objectives and scope of the European Biotech Act

They understood how the immune system is kept in check: The 2025 Nobel prize in physiology or medicine

NovalGen to Begin World’s First Clinical Trial for a Self-Regulating Immunotherapy with Mabion manufacturing capacity.

Mabion Participates in Groundbreaking Clinical Trial of Self-Regulating Immunotherapy

Cancer Reversion Therapy is groundbreaking new strategy instead aims to reprogram tumor cells back into normal cells, potentially overcoming drug resistance and side effects associated with cell-killing therapies. Research demonstrates that inhibiting a few key genetic “switches” can induce malignant colon cells to differentiate into benign intestinal cells, effectively reversing their cancerous state.

Reprogramming Cancer Cells: A New Paradigm in Colon Cancer Reversion Therapy

Modulation of the immune system to treat cancer and on novel approaches to further extend the efficacy of current and emerging immunotherapies led us to our current understanding of the melanoma immune microenvironment in humans and the mechanistic work supporting these observations.

Melanoma Immunotherapy Enhance by Immunity Activation

Gastric cancer treatment

Zolbetuximab demonstrates significant benefit in gastric cancer and receives approval in the EU